NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis $1.27 -0.03 (-2.31%) As of 03/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Eliem Therapeutics Stock (NASDAQ:ELYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eliem Therapeutics alerts:Sign Up Key Stats Today's Range$1.25▼$1.3250-Day Range$1.25▼$2.0152-Week Range$2.35▼$11.55Volume70,325 shsAverage Volume486,688 shsMarket Capitalization$37.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More… Remove Ads Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELYM Stock News HeadlinesEliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2, 2024 | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. March 28, 2025 | Golden Portfolio (Ad)Eliem Therapeutics: Recent Strategic Pipeline RestructuringSeptember 23, 2024 | seekingalpha.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 11, 2024 | globenewswire.comEliem Therapeutics Announces Additions to its Leadership TeamAugust 26, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsAugust 14, 2024 | globenewswire.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 24, 2024 | finance.yahoo.comSee More Headlines ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed this year? Eliem Therapeutics' stock was trading at $1.80 at the beginning of the year. Since then, ELYM shares have decreased by 29.4% and is now trading at $1.27. View the best growth stocks for 2025 here. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.19. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eliem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings11/08/2021Today3/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELYM CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.03% Return on Assets-45.97% Debt Debt-to-Equity RatioN/A Current Ratio60.41 Quick Ratio60.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book0.34Miscellaneous Outstanding Shares29,752,000Free Float28,354,000Market Cap$39.27 million OptionableNot Optionable Beta-0.39 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:ELYM) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.